Efficacy of Glimepiride/Metformin Fixed-Dose Combination Versus
Metformin Uptration in Type 2 Diabetic Patients Inadequately
Controlled on Metformin Monotherapy, a Randomized, Multicenter,
Parallel-Group, Open Study in Korea
Year: 2011
Abstract Number: 2275-PO
Authors: HYE-SOON KIM, DOO MAN KIM, BONG SOO CHA, TAE SUN PARK,
KYOUNG-AH KIM, DONG-LIM KIM, CHOON HEE CHUNG, JEONG HYUN PARK, HAK
CHUL JANG, DONG-SEOP CHOI
Institutions: Daegu, Republic of Korea, Seoul, Republic of
Korea, Jeon-ju, Republic of Korea, Ilsan, Republic of Korea, Wonju,
Republic of Korea, Pusan, Republic of Korea, Bundang, Republic of
Korea
Results: The aim of this study was to compare the efficacy and
safety of early combination therapy with glimepiride/metformin to
metformin uptitration in reducing HbA1c levels from baseline over
24 weeks. A randomized, multicenter, parallel-group, open study was
performed with arms of glimepiride/metformin (initial dosage 2/500
mg/day) and metformin uptitration (initial dosage 1,000 mg/day) in
type 2 diabetic patients inadequately controlled by metformin
monotherapy. Dosage was titrated to a maximum (8/2,000 mg and 2,500
mg, respectively) in order to reach the glycemic control goals
(140200 mg/dL of self monitored blood glucose without
hypoglycemia). Serum hemoglobin A1c (HbA1c), fasting and
postprandial glucose were measured for efficacy analysis. In all,
209 patients were randomized (glimepiride/metformin, n=101;
metformin uptitraion, n=108). There was no significant difference
in baseline characteristics between groups. At the end of the
study, adjusted mean change in HbA1c level was significantly higher
in the glimipiride/metformin group than metformin uptration group:
-1.2% and -0.93%, respecvively (P
